GILD

Gilead Sciences
D

GILD

92.060
USD
-0.89
(-0.96%)
مفتوح الان
حجم التداول
30,645
الربح لكل سهم
8
العائد الربحي
3.31
P/E
1,023
حجم السوق
114,731,234,795
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ شهرين
    buy
    GILD
    GILD
    2024-10-30 14:50
    GILD Chart
    المزيد
أصول ذات صلة
    ABBV
    ABBV
    -2.830
    (-1.64%)
    169.920 USD
    AMGN
    AMGN
    -1.37
    (-0.50%)
    273.66 USD
    BIIB
    BIIB
    1.520
    (1.08%)
    142.460 USD
    BMY
    BMY
    -0.310
    (-0.54%)
    56.740 USD
    GSK
    GSK
    -0.110
    (-0.33%)
    33.670 USD
    JNJ
    JNJ
    -4.725
    (-3.19%)
    143.350 USD
    MRK
    MRK
    -0.350
    (-0.36%)
    95.790 USD
    PFE
    PFE
    -0.241
    (-0.90%)
    26.385 USD
    REGN
    REGN
    6.92
    (1.01%)
    694.24 USD
    المزيد
الأخبار
المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).